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Abstract
Carpal tunnel syndrome (CTS) is a neuropathy due to the compression of the median nerve. 
It is shown that gabapentin in high doses is effective in treatment of CTS patients. In this study 
we evaluated the efficacy of low doses of gabapentin in treatment of CTS patients. Ninety 
patients with CTS were randomly assigned to groups A, B and C. Gabapentin was administered 
to group A with dose of 100 mg/day and to group B with dose of 300 mg/day for 2 months. 
Group C received no treatment. Before and after treatment, patients were evaluated using Visual 
analogue scale (VAS) for pain and parasthesia, Boston carpal tunnel questionnaire (BCTQ) 
including Symptom Severity Scale (SSS) and Functional Status Scale (FSS) to evaluate the 
efficacy of the treatment. The pinch and grip strength was also measured. There was significant 
improvement in VAS, grip strength, pinch strength, SSS, FSS and BCTQ score in all three 
groups (p < 0.05), but the changes in CMAP and SNAP was not significant. Groups A and B in 
comparison to group C had significantly better improvement in VAS, pinch strength, SSS, FSS 
and BCTQ total score (p < 0.05). There was significantly more improvement in pinch strength 
and SSS score in group B compared to group A (p < 0.05). Gabapentin in low doses is a useful 
drug in treatment of CTS symptoms with no side effects and intolerance. Gabapentin with dose 
of 300 mg/day is more effective than the dose of 100 mg/day.
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Introduction
Carpal tunnel syndrome (CTS) is one of the 
most common entrapment neuropathy which 
results from the compression of the median nerve 
at the carpal tunnel level in the wrist (1, 2). CTS 
symptoms are paresthesia (which is commonly 
exacerbated at night), numbness, tingling, pain 
(more often nocturnal) and weakness (1-4). 
Diagnosis is based on clinical presentation and 
confirmed by electrodiagnostic studies (2, 5).
It is critical to begin treating early phases 
of carpal tunnel syndrome before the damage 
progresses. Initial therapies for CTS include 
oral or local injection of corticosteroids, 
NSAIDS, splinting and activity modification 
(6). The anticonvulsants such as pregabalin 
and gabapentin are proposed for the treatment 
of neuropathic pain (7-10). Gabapentin use 
is shown to be safe and effective in CTS (as a 
neuropathy) (11-14). These studies have used 
gabapentin with high doses (900-1800 mg/day) 
which would have some side effects and is not 
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at nights for all 3 groups during the study. The 
physician evaluating the treatment outcome 
was blinded to the regimens. The possible side 
effects were also monitored to assess the safety 
of the drug. Patients were asked to report or visit 
the clinic if any adverse effects appeared during 
the study period. At baseline and at the end of the 
2 months treatment period, patients were asked 
to complete Boston carpal tunnel questionnaire 
(BCTQ) to evaluate the efficacy of the treatment. 
The pain and parasthesia was measured with 
visual analogue scale (VAS). Pinch and grip 
strength were also measured using dynamometer.
Boston carpal tunnel questionnaire (BCTQ), 
a self-administered disease-specific outcome 
instrument, was used to assess the severity 
of symptoms and the functional status. The 
question naire consists of two multi-item 
scales: the Symptom Severity Scale (SSS) 
and the Functional Status Scale (FSS). The 
SSS evaluates symptoms like pain, numbness, 
weakness, paraesthesia, or clumsiness and over-
all functional status using 11 questions. The FSS 
evaluates difficulties with daily activities like 
writing, buttoning clothes, holding a book while 
reading, gripping a telephone handle, opening 
jars, household chores, carrying grocery bags, 
and bathing/ dressing using eight questions. 
The SSS consisted of responses numbered 1 
(no symptoms) to 5 (most severe). The FSS 
consisted of responses numbered 1 (performance 
with no difficulty) to 5 (unable to perform due to 
symptoms). The overall SSS and FSS scores are 
calculated as the mean of the scores. 
Pain and paresthesia was measured using a 10 
cm visual analogue scale (VAS). Pain intensity is 
referred as 0 to 10, in which 0 = no pain at all and 
10 = the worst pain possible. Patients were asked 
to sign on the VAS scale that corresponded their 
pain. Grip strength was measured by a Lafayette 
hand dynamometer and pinch strength was 
determined by Lafayette Hydraulic Pinch Gauge 
(3700 Sagamore Parkway North, Lafayette, 
Indiana, USA).
Electrodiagnostic assessment was carried 
out using a ‘Medelec TECA synergy’ 
electromyography device, controlling the 
skin temperature at 32°C. Electrodiagnostic 
data, including distal latency and amplitude of 
‘compound motor action potential’ (CMAP) 
tolerable by some patients. There is a possibility 
that gabapentin reach satisfactory results with 
low doses. To evaluate this presumption, we aim 
to evaluate the efficacy of 100 mg/day and 300 
mg/day gabapentin in the symptom alleviation in 
patients with CTS.
Experimental
Methods
In this randomized clinical trial we studied 
90 consecutive patients with mild to moderate 
CTS (70 women and 20 men, mean age 44.38 ± 
8.26 years, range, 22-68 years) visiting Physical 
Medicine and Rehabilitation clinics, Tabriz 
University of Medical sciences, Tabriz, Iran. 
Clinical diagnosis of CTS was based on the 
American Academy of Neurology diagnostic 
criteria (15). Comprehensive medical and 
neurological evaluations were performed 
to exclude neuropathies of other etiologies. 
Patients with isolated CTS were included in 
the study and patients with CTS in the setting 
of other neurological diseases were excluded. 
Patients who had thenar atrophy or were treated 
with steroid injection in the last 3 months, with 
known contraindication to or prior use of any 
antiepileptic drugs, creatinine clearance <30 
mL/min or elevated liver enzymes, clinically 
significant hematologic, cardiovascular, renal, 
or hepatic disease, history of narcotic or alcohol 
abuse and previous CTS surgery were also 
excluded. The protocol was approved by the 
local ethics committee of our institution, and the 
informed consent was obtained from all study 
participants. This clinical trial was registered 
in the Iranian Clinical Trial Registry, and the 
registry number is IRCT201401144641N7.
Using RANDLIST 1.2 software, random 
numbers were produced and according to sample 
size, patients were enrolled into the study. In 
the case of missing or exclusion of any patient 
during the course of treatment, a new patient 
was selected by more random numbers. Patients 
with mild to moderate CTS randomly divided 
into 3 groups A and B and C. For a period of 2 
months, Group A received gabapentin 100 mg/
day (Soha Pharmaceutical Co., Iran), Group B 
received gabapentin 300 mg/day and group C 
received no treatment. Splints were administered 
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and ‘sensory nerve action potential’ (SNAP) 
of the median nerve were derived from 
electrodiagnostic study reports and recorded on 
the patient’s data form. 
Statistical analysis
Statistical analyses were performed using the 
Statistical Package for Social Sciences, version 
17.0 (SPSS, Chicago, Illinois). A p value of < 
0.05 was considered statistically significant.
Results and Disscusion
Ninety patients with CTS were evaluated in 
three therapeutic groups. Table 1 demonstrates 
baseline findings between groups. There was no 
significant difference between groups. The initial 
presenting symptoms of CTS were numbness 
(95.5%), tingling (91.1%) and nocturnal 
worsening of symptoms (90%). Phalen›s and 
Tinel›s sign were positive in 82.2% and 71.1% 
of patients, respectively. 
The changes in the studied parameters 
before and after treatment are shown in Table 2. 
Before the treatment, there were no significant 
differences between groups while after the 
treatment there were significant differences in 
VAS, strength, pinch, SSS, FSS and total BCTQ 
score between groups. After the treatment, 
Group A and B in comparison to group C had 
Group A Group B Group C P value
Age (years) 42.46 ± 8.16 44.56 ± 8.58 46.34 ± 8.08 NS
Gender, Female 24 (80%) 21 (70%) 25 (83.3%) NS
Mean duration of illness 21.56 ± 7.34 20.32 ± 7.93 21.33 ± 7.45 NS
Dominant hand
Right 28 (93.3%) 23 (76.7%) 27 (90%)
NS
Left 2 (6.7%) 7 (23.3%) 3 (10%)
Involved hand
Right 18 (60%) 18 (60%) 19 (63.3%)
NS
Left 12 (40%) 12 (40%) 11 (36.7%)
Table 1. Patients’ baseline findings.
NS: Not significant.
Group A Group B Group C P value
VAS
Before 5.63 ± 2.02 4.93 ± 2.34 5.70 ± 2.11 NS
After 1.96 ± 1.66 1.55 ± 1.47 3.37 ± 1.94 <0.001*
Grip Strength
Before 21.94 ± 4.74 22.27 ± 4.53 23.11 ± 3.50 NS
After 25.38 ± 4.47 25.94 ± 4.26 24.60 ± 3.33 NS
Pinch strength
Before 4.31 ± 0.67 4.27 ± 1.05 4.02 ± 0.65 NS
After 5.67 ± 0.73 6.08 ± 0.90 4.50 ± 0.85 <0.001*
SSS
Before 3.50 ± 0.43 3.65 ± 0.33 3.48 ± 0.56 NS
After 2.41 ± 0.52 2.19 ± 0.43 2.86 ± 0.51 <0.001*
FSS
Before 4.32 ± 0.52 4.36 ± 0.54 4.12 ± 0.47 NS
After 3.22 ± 0.95 3.17 ± 0.72 3.70 ± 0.56 0.02*
BCTQ total
Before 7.83 ± 0.87 8.01 ± 0.83 7.60 ± 0.89 NS
After 5.70 ± 1.34 5.36 ± 0.98 6.57 ± 0.87 <0.001
CMAP
Before 4.17 ± 0.42 4.98 ± 0.76 4.49 ± 0.42 NS
After 4.17 ± 0.44 5.78 ± 1.58 4.46 ± 0.41 NS
SNAP
Before 3.49 ± 0.29 4.49 ± 0.95 4.65 ± 1.05 NS
After 3.46 ± 0.32 4.72 ± 1.20 3.56 ± 0.37 NS
Table 2. Changes in the studied parameters before and 2 months after treatment.
VAS: Visual analogue scale; SSS: Symptom Severity Scale; FSS: Functional Status Scale; BCTQ: Boston carpal tunnel questionnaire; 
CMAP: Compound motor action potential; SNAP: Sensory nerve action potential; NS: Not significant.
*p is two-sided significant.
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significantly lower VAS, SSS, FSS and BCTQ 
total and higher pinch strength (p < 0.05), but 
the differences between group A and B were 
not significant. Comparing the results before 
and after treatment, we observed significant 
improvement in VAS, grip strength, pinch 
strength, SSS score, FSS score and BCTQ score 
in all three groups (p < 0.001 in all variables in 
each groups); however there were no significant 
changes in CMAP and SNAP.
In order to evaluate the more effective 
treatment between groups, we evaluated the 
percent of improvement in each variable 
between groups (Table 3). There were significant 
differences between groups in all evaluated 
parameters (p < 0.001). Groups A and B in 
comparison to group C had significantly better 
improvement in VAS, pinch strength, SSS, 
FSS and BCTQ total (p < 0.001). Comparing 
the results between group A and B, there were 
significantly more improvement in pinch 
strength and SSS score group B (p < 0.05), but 
the differences between groups in other variables 
were not significant.
We observed no side effects during the study 
period in any of the subjects and all subjects had 
a good compliance to the treatment.
Gabapentin is an effective drug for treatment 
of neuropathic pain and has been reported to be 
effective in various disease including trigeminal 
neuralgia, postherpetic neuralgias, diabetic 
neuropathy and after surgeries especially 
orthopedic and neurosurgery (9, 16, 17). The 
drug’s effect in improving neuropathic pain has 
encouraged many others to use gabapentin in 
other diseases with neuropathy basis including 
CTS (11-14).
In this prospective randomized clinical trial 
we evaluated the effects of low dose gabapentin 
(100 mg and 300 mg) in controlling pain and 
improving symptoms of patients with CTS. 
Following treatment with gabapentin 100 and 
300 mg per day, patients reported significant 
decrease in pain severity and BCTQ subscores 
(p < 0.001). There was also a significant increase 
in pinch and grip strength (p < 0.001).
There are few studies evaluating gabapentin 
effects on relieving CTS symptoms which are 
performed with high doses of gabapentin (11-
14). Taverner et al. (11) reported significant 
improvement in signs and symptoms of CTS in 
84.2% of their patients (n = 19) with gabapentin 
1800 m/day during 6 months follow-up. Duman 
et al. (12) reported a reduction in symptoms in 
21 patients with CTS patients treated for three 
months using gabapentin with average dose of 
648 mg/day. Erdemoglu (13) in a study of 41 
patients with CTS reported significant decrease 
in SSS and FSS and total BCTQ during follow-
up using 1800 mg/day gabapentin. However, all 
these three previous studies were single group 
study with no control group and randomization. 
The recent randomized clinical trial by Hui 
and colleagues (14) also showed significant 
differences between gabapentin (300-900 mg/
day) and placebo group in 2 weeks, but by eight 
weeks they observed no significant improvement 
(14). In our study at the end of eight week trial 
we observed significantly better improvement in 
patients receiving gabapentin 100 or 300 mg in 
comparison to control group (p < 0.001).
The recommended and tolerable dosage of 
gabapentin in the literature is reported between 
900 and 3600 mg per day (11). However the 
higher doses would have some adverse effects 
and not well tolerated by all patients which can 
Group A Group B Group C P value
VAS -70.08 ± 20.72% -75.57 ± 20.79 -45.78 ± 19.60 <0.001*
Grip strength 17.25 ± 12.49% 17.51 ± 8.95% 6.84 ± 4.74% <0.001*
Pinch strength 33.30 ± 18.67% 49.81 ± 28.17% 15.43 ± 4.60% <0.001*
SSS -30.74 ± 14.23 -39.46 ± 13.67 -16.62 ± 13.86 <0.001*
FSS -24.63 ± 17.91 -27.16 ± 15.33 -9.71 ± 12.46 <0.001*
BCTQ total -27.45 ± 14.07 -32.78 ± 12.35 -13.12 ± 9.97 <0.001*
Table 3. Rate of improvement in studied variables between groups.
VAS: Visual analogue scale; SSS: Symptom Severity Scale; FSS: Functional Status Scale; BCTQ: Boston carpal tunnel questionnaire 
*p is two-sided significant.
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could be recommended to use 300 mg/day for 
more beneficiary results.
Conclusion
In conclusion, gabapentin is a useful drug 
in treatment of CTS symptoms which can be 
used with low doses and have no side effects 
and intolerance. Using gabapentin with dose 
of 300 mg/day in comparison to 100 mg/day 
is recommended because of more satisfactory 
results during the treatment. 
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